Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

Application US20260078091A1 Kind: A1 Mar 19, 2026

Inventors

Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu

Abstract

The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

CPC Classifications

C07D 211/76 C07D 221/20 C07D 279/02 C07D 401/04 C07D 401/06 C07D 401/12 C07D 405/04 C07D 405/12 C07D 407/04 C07D 407/06 C07D 409/04 C07D 409/12 C07D 413/06 C07D 417/06 C07D 417/12 C07D 417/14 C07D 471/10 C07D 491/08 C07D 491/153 C07D 498/08 C07D 498/14 C07D 498/20

Filing Date

2025-03-04

Application No.

19070108

View original document →